A green background with a white border. White text at the top says: 2025 Annual Report Below text says: The board voted to approve the 2025 Annual Report for the Oregon Legislature. The report outlines the board's activities, price trend analyses, and policy recommendations to improve drug affordability across Oregon. To the right is a screenshot of the yellow report cover with a photo of a family.

A green background with a white border. White text at the top says: 2025 Affordability Reviews. Below text says: Board members identified several top priority drugs that present significant affordability challenges for Oregonians: Cosentyx Creon Vraylar Trulicity Lantus SoloStar Their final vote will be at their January 21 meeting. Icons of an injection, pills, and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Next Year. Below text says: The board is already preparing for 2026 affordability reviews, developing a preliminary list of 137 drug products for review based on 2024 data. To ensure patient voices are heard, a major outreach project will launch in spring of 2026 with community meetings in Salem, Redmond, Portland, and Beaverton, and online. An icon of the state of Oregon with hands raised inside. A speech bubble coming from the state with a pill bottle and a price tag with three dollar signs.

A green background with a white border. White text at the top says: Looking Ahead. White text below says: Next PDAB Meeting: January 21, 2026 at 8 am, Register for Zoom Link. Board members will vote on the final list of unaffordable drugs from their 2025 affordability reviews. A white icon of a calendar with the date January 21.

This Wednesday the #Oregon #PDAB met. Here are the highlights:
- Annual Report
- 2025 #Affordability Reviews
- Next Year's Plan

Next meeting: Jan 21, 2026 at 8 am. Zoom link at dfr.oregon.gov/pdab

#Cosentyx #Creon #Vraylar #Trulicity #LantusSoloStar #HealthPolicy

A red rectangle at the top of the page with a white icon of a calendar with a clock and text that says PDAB public comments are due on Monday Oct, 13 at 8 am! Below is a light blue icon of a paper with a dollar sign and a down arrow. White background with black text says The Oregon Prescription Drug Affordability Board (PDAB) is reviewing high-cost drugs to determine if they strain Oregon patients or our healthcare system at their October 15 meeting. If you or someone you know has paid a high price for any of these Insulin Glargine products: Basaglar KwikPen Insulin Glargine-yfgn Lantus Lantus SoloStar Semglee (yfgn) Toujeo Max SoloStar Toujeo SoloStar Consider sharing you experience with the Oregon PDAB at the link. A teal arrow points to the right. An icon of an internet search bar with red text that says: bit.ly/or-pdab-comment

Pale pink background, title reads" TIPS FOR PDAB PUBLIC TESTIMONY" Start with your name and where you live Example: “Hello, my name is Jamie Lee and I live in Eugene.” Name the prescription drug you're speaking about Example: “I’m here to talk about the cost of Humira.” Explain your coverage (if any) Example: “I have private insurance, but I still pay over $300 a month.” Share how the cost impacts you Example: “I sometimes skip doses to stretch out my prescription because I can't afford to refill it on time.” Ask the board to act and say thank you Example: “Please consider how the cost affects real people like me. Thank you.”

Reminder to submit public comment to the next #Oregon Prescription Drug Affordability Board (#PDAB) meeting before Monday at 8 am! Link to submit comments: bit.ly/or-pdab-comment

#BasaglarKwikPen #InsulinGlargineyfgn #Lantus #LantusSoloStar #Semgleeyfgn #ToujeoMaxSoloStar #ToujeoSoloStar

Pale yellow background, black text reads Have you or someone you know paid a high price for: Lantus SoloStar or Lantus a dark purple box with a lavendar insulin vial icon, lavendar insulin pen icon and white text reads Lantus SoloStar or Lantus Generic: None Therapy Class: Insulin. Below the box black text reads Consider sharing your story with the Oregon Prescription Drug Affordability Board

Have you or someone you know paid a high price for #LantusSoloStar or #Lantus?

The #Oregon #PDAB is reviewing high-cost drugs that may strain Oregon patients & they need to hear from YOU! The next meeting is Oct 15 @ 8 am.

Comment at: bit.ly/or-pdab-comment

#HealthPolicySky #Insulin #Diabetes